Standout Papers

Safety and Immunogenicity... 2024 2026 2024 10 20 30

Immediate Impact

2 hit

Citing Papers

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
2024 Hit
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
2024 Hit

Works of Rakesh Dhar being referenced

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults
2024 Hit
Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial
2024

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Rakesh Dhar 62 52 18 17 13 9 96
Scott A. Rush 90 1.5× 78 1.5× 17 0.9× 6 0.4× 14 1.1× 9 125
Karla R. Navarro-Fuentes 35 0.6× 38 0.7× 11 0.6× 12 0.7× 8 0.6× 6 90
Iría Miguens 37 0.6× 39 0.8× 5 0.3× 20 1.2× 4 0.3× 10 83
Charlotte Vernhes 107 1.7× 37 0.7× 18 1.0× 37 2.2× 5 0.4× 9 145
Elena V. Shidlovskaya 19 0.3× 64 1.2× 22 1.2× 12 0.7× 4 0.3× 13 89
Karlijn van der Straten 19 0.3× 75 1.4× 13 0.7× 9 0.5× 12 0.9× 9 110
Gisèle Elana 35 0.6× 63 1.2× 18 1.0× 8 0.5× 10 0.8× 7 223
Jesse Miller 96 1.5× 111 2.1× 32 1.8× 11 0.6× 11 0.8× 10 218
IA Shulman 84 1.4× 15 0.3× 16 0.9× 13 0.8× 12 0.9× 13 245
Maria Overvad 32 0.5× 150 2.9× 44 2.4× 9 0.5× 9 0.7× 11 241

All Works

Loading papers...

Rankless by CCL
2026